Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | DHPS | P49366 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.38 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2024051 | 0.94 | HDAC4 (0.44) | GRM2MEN1KMT2AHDAC4HDAC1 | |
| SCHEMBL2024513 | 0.93 | DHPS (0.46) | GRM2MEN1KMT2AHDAC4HDAC1 | |
| SCHEMBL2028118 | 0.93 | GRM2 (0.43) | GRM2MEN1KMT2AHDAC4HDAC1 | |
| SCHEMBL1091219 | 0.91 | GRM2 (0.41) | GRM2MEN1KMT2AHDAC4HDAC1 | |
| SCHEMBL2024174 | 0.89 | MEN1 (0.51) | GRM2MEN1KMT2AHDAC4HDAC1 | |
| SCHEMBL2026332 | 0.87 | GRM2 (0.43) | GRM2MEN1KMT2AHDAC4HDAC1 | |
| SCHEMBL8270193 | 0.87 | GRM2 (0.57) | GRM2MEN1KMT2AHDAC4HDAC1 | |
| SCHEMBL2023144 | 0.86 | DHPS (0.41) | GRM2MEN1KMT2AHDAC4HDAC1 | |
| SCHEMBL2026834 | 0.86 | DHPS (0.48) | GRM2MEN1KMT2AHDAC4HDAC1 | |
| SCHEMBL1091638 | 0.86 | GRM2 (0.43) | GRM2MEN1KMT2AUSP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807706-B2 | Metabotropic glutamate-receptor-potentiating isoindolones | ASTRAZENECA AB (SE) | 2010-10-05 | — | — | US | claimed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | claimed |
| EP-1912939-A1 | METABOTROPIC GLUTAMATE-RECEPTOR-POTENTIATING ISOINDOLONES | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | claimed |
| WO-2007021308-A1 | METABOTROPIC GLUTAMATE-RECEPTOR-POTENTIATING ISOINDOLONES | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | claimed |
| US-8153638-B2 | Metabotropic glutamate-receptor-potentiating isoindolones | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-8153638-B2 | Metabotropic glutamate-receptor-potentiating isoindolones | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-8153638-B2 | Metabotropic glutamate-receptor-potentiating isoindolones | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| EP-1912939-A1 | METABOTROPIC GLUTAMATE-RECEPTOR-POTENTIATING ISOINDOLONES | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007021308-A1 | METABOTROPIC GLUTAMATE-RECEPTOR-POTENTIATING ISOINDOLONES | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | GRM2 4/4885MEN1 2588/4885KMT2A 3975/4885 |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | GRM1, GRIN1, GRM2 | GRM2 3/4885MEN1 2958/4885KMT2A 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.